5 Stocks To Invest In According To Stephen Errico’s Locust Wood Capital

Page 1 of 5

In this article, we discuss the 5 stocks to invest in according to Stephen Errico’s Locust Wood Capital. If you wish to see our detailed analysis of Errico’s history, investment philosophy, and hedge fund performance, go directly to the 10 Stocks To Invest In According To Stephen Errico’s Locust Wood Capital.

5. Boston Scientific Corporation (NYSE:BSX)

Locust Wood Capital’s Stake Value: $67.7 million
Percentage of Locust Wood Capital’s 13F Portfolio: 3.67%
Number of Hedge Fund Holders: 51

Boston Scientific Corporation (NYSE:BSX) is a Massachusetts-based manufacturing company that designs, produces and sells devices for interventional medical specialties, including interventional radiology.

On October 6, Piper Sandler analyst Matt O’Brien maintained an Overweight rating on Boston Scientific Corporation (NYSE:BSX) with a $175 price target on its shares.

As of the end of the third quarter of 2021, Stephen Errico’s Locust Wood Capital reported holding over 1.56 million shares of Boston Scientific Corporation (NYSE:BSX). These shares amount to $67.7 million and represent 3.67% of the investment firm’s portfolio.

Of the 873 elite funds tracked by Insider Monkey, 51 held stakes in the company in the second quarter of 2021, up from 44 hedge funds in the preceding quarter.

Out of the hedge funds being tracked by Insider Monkey, Andreas Halvorsen’s Viking Global is the biggest stakeholder in Boston Scientific Corporation (NYSE:BSX), with over 13.3 million shares worth approximately $569.3 million.

Artisan Partners, in its second-quarter investor letter mentioned Boston Scientific Corporation (NYSE:BSX). Here is what the fund said:

“Among our top contributors (includes) Boston Scientific. Shares of Boston Scientific were volatile throughout most of 2020 as the pandemic drove significant drops in elective medical procedures, though our longer-term constructive view and belief elective medical procedures would bounce back post pandemic prompted us to add to our position. We have been rewarded with shares rebounding this year alongside a recovery in elective medical procedures. Longer-term, we believe the company’s investments in higher growth categories will drive revenue growth to the higher end of its peer group with rising margins.”



Page 1 of 5